The importance of patient-reported outcomes in clinical trials and strategies for future optimization
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Patient-reported outcomes (PROs) can be included in clinical trials as primary or secondary endpoints and are increasingly recognized by regulators, clinicians, and patients as valuable tools to collect patient-centered data. PROs provide unique information on the impact of a medical condition and its treatment from the patient's perspective; therefore, PROs can be included in clinical trials to ensure the impact of a trial intervention is comprehensively assessed. This review first discusses examples of how PRO endpoints have added value to clinical trial interpretation. Second, it describes the problems with current practices in designing, implementing, and reporting PRO studies, and how these problems may be addressed by complying with guidance for protocol development, selecting appropriate PRO measures to match clinically motivated PRO hypotheses, minimizing the rates of avoidable missing PRO data, analyzing and interpreting PRO data, and transparently reporting PRO findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The weaRAble-PRO study administered a selection of validated PRO measures for RA in complement to bespoke digital PRO assessments—that are validated in clinical trials”
From Digital health technologies and machine learning augment patient reported outcomes to remotely characterise rheumatoid arthritis (2024) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363 · cited 2×
“It should be used in conjunction with the SPIRIT 2013 statement 32,33 when developing a research protocol for a trial with a primary or important secondary PRO endpoint.”
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251 · cited 2×
“It should be used in conjunction with the SPIRIT 2013 statement 32,33 when developing a research protocol for a trial with a primary or important secondary PRO endpoint.”
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000251 · Cited by 2,296
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580 · cited 2×
“21,22 The PRO endpoints led to regulatory approval of mitoxantrone for this indication and wide implementation in the clinic.”
InfluentialSelf-citationReporting of Patient-Reported Outcomes in Randomized Trials: The CONSORT PRO Extension
Calvert, M., Blazeby, J., Altman, D. G., Revicki, D. A., Moher, D., Brundage, M. D., & CONSORT PRO Group, F. T. (2013) · JAMA · doi:10.1001/jama.2013.879 · Cited by 1,386 · cited 2×
“This work informed the development of a CONSORT-PRO Extension (Consolidated Standards of Reporting Trials), which can be considered the minimum reporting items for PRO endpoints (primary or key secondary) in RCTs. 73 CONSORT-PRO consists of 14 items, five of which were newly developed PRO-specific reporting recommenda…”
Self-citationReducing waste from incomplete or unusable reports of biomedical research
Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., Michie, S., Moher, D., & Wager, E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62228-x · Cited by 1,319 · cited 1×
“However, the issue of non-reporting of PROs is emerging and requires attention, as it is unethical to waste the funding, resources, and patients’ efforts expended in PRO data collection.(71)”
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818 · cited 2×
“In oncology, for example, the American Society of Clinical Oncology (ASCO)(10) and European Society for Medical Oncology (ESMO)(11) have proposed standardized approaches to evaluate clinical trial results by using scores to evaluate the Magnitude of Clinical Benefit (ESMO MCB) or the Net Health Benefit (ASCO), which i…”
Calvert, M., Kyte, D., Mercieca-Bebber, R., Slade, A., Chan, A.-W., King, M. T., and the SPIRIT-PRO Group, Hunn, A., Bottomley, A., Regnault, A., et al. (2018) · JAMA · doi:10.1001/jama.2017.21903 · Cited by 814 · cited 5×
“A second review examined the PRO content of 26 protocols of Phase III international, ovarian cancer trials published between 2000 and 2016 against a list of PRO-specific items that would eventually inform the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)-PRO Extension.(29,30) Of the 26 tr…”
InfluentialSelf-citation
Research works printed but not linked: 2
- [15]Food and Drug Administration Ovarian Cancer Endpoints Workshop April 26, 2006, Meeting Summary 2006 Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/Developmen-tResources/CancerDrugs/ucm094598.pdf accessed 09 August 2016 https://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm120657.pdf Accessed 14 August 2017.v
- [56]Mercieca-Bebber R Palmer MJ Brundage M Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review BMJ Open 2016 6 6 e010938 PMC4916640 27311907
Cited by
Items 301–400 of 660
Thomas, R. J., Yerkovich, S. T., Goyal, V., Chang, A. B., Rutter, C., Masters, I. B., & Marchant, J. M. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.26940 · Cited by 4
Identifying Palliative Care Needs in Patients With Heart Failure Using Patient Reported Outcomes
Lykke, C. C., Jurlander, B., Ekholm, O., Sjøgren, P., Juhl, G. I., Kurita, G. P., Larsen, S., Tønder, N., Høyer, L. V., Eidemak, I., et al. (2024) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2024.09.002 · Cited by 6
Enhancing pediatric oncology clinical trials through patient reported outcomes (PROs)
Riedl, D., Hubel, N. J., Endres, A., Vetrano, C., Meryk, A., & Crazzolara, R. (2024) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2024.100199 · Cited by 4
Sapmaz, A., Paik, A., Henry, L. L., & Younossi, Z. M. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.70 · Cited by 10
Wuyts, J., Foulon, V., Allemann, S. S., & Boeni, F. (2025) · BMC Health Services Research · doi:10.1186/s12913-024-12024-6 · Cited by 5
Shin, D., Meade, S. M., Scariano, G. N., Li, Y., Patel, A., Lapin, B. R., Steinmetz, M. P., Mroz, T. E., & Habboub, G. (2025) · The Spine Journal · doi:10.1016/j.spinee.2025.04.022 · Cited by 5
“In the context of clinical trials using PROMs to assess outcomes, centralized monitoring systems have shown success in improving PROM completion, as has the implementation of routine study updates to patients [20].”
Graham, A., Knapp, R., RODD, H. D., Marshman, Z., Zaitoun, H., & Gilchrist, F. (2021) · Oral · doi:10.3390/oral1040028 · Cited by 4
Patient Reported Outcomes and Measures in Children with Rhabdomyosarcoma
van Gorp, M., Grootenhuis, M. A., Darlington, A., Wakeling, S., Jenney, M. E. M., Merks, J. H. M., Hjalgrim, L. L., & Adams, M. K. M. (2023) · Cancers · doi:10.3390/cancers15020420 · Cited by 4
Looijen, A. E. M., van Linschoten, R. C. A., Brugma, J.-D. C., Hijnen, D., de Jong, P. H. P., van der Kuy, P. H. M., van Laar, J. A. M., van der Woude, C. J., & Pasma, A. (2023) · JMIR Research Protocols · doi:10.2196/43230 · Cited by 5
“Electronic distribution of surveys before and during outpatient clinic visits has several benefits [28]: (1) patients can fill them out at home, (2) it streamlines the data-entry process, and (3) it allows for computer adaptive testing to reduce user burden.”
Vanderhout, S. M., Potter, B. K., Smith, M., Butcher, N. J., Vaters, J., Chakraborty, P. K., Adams, J., Inbar‐Feigenberg, M., Offringa, M., Speechley, K. N., et al. (2023) · Quality of Life Research · doi:10.1007/s11136-023-03393-2 · Cited by 5
Tsoukas, D., Muntean, I., Simos, C., & Sabido-Vera, R. (2023) · Bioengineering · doi:10.3390/bioengineering10111294 · Cited by 4
Unveiling Assessment Gaps in Parkinson's Disease Psychosis: A Scoping Review
Mangone, G., Tosin, M. H. D. S., Goetz, C. G., Stebbins, G. T., & Mestre, T. (2024) · Movement Disorders · doi:10.1002/mds.29710 · Cited by 4
“27 To emphasize the value of PROs, we present the example of Charles Bonnet syndrome.”
MethodYang, M., Liu, Y., Zhao, Y., Wang, Z., He, J., Wang, Y., & Anme, T. (2024) · International Journal of COPD · doi:10.2147/copd.s444580 · Cited by 5
“12 PROs are any report provided directly by the patient regarding their health status, 13 including symptoms, functional status, and health-related quality of life (HRQoL).”
BackgroundVilaplana, A., Daniel, M. M., Valero‐Arrese, L., Marshall, L. V., Rovira, A. S., Crowe, T., Romero, L., de Rojas, T., Carceller, F., & Moreno, L. (2024) · Pediatric Blood & Cancer · doi:10.1002/pbc.31165 · Cited by 4
Adegboye, O., Churchill, J. A., Moorjani, J., Johnson, H., Capper, S., Booker, J., Parnham, A. S., Lau, M., Sangar, V., & Finn, C. F. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102168 · Cited by 4
Citrome, L., Suett, M., Franzenburg, K. R., Eshet, R., Elgart, A., rd, G. D., Harary, E., Tohami, O., Mychaskiw, M. A., & Kane, J. M. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s459104 · Cited by 4
“…prior TV-46000 treatment cohorts, total scores decreased in the de novo cohort (–1.93 [0.52]; –0.68 [0.52]), increased in the placebo rollover cohort (0.55 [0.65]; 1.01 [0.61]), and, on average, remained unchanged in the TV-46000 rollover cohort (0.06 [0.36]; –0.25 [0.35]) (Table 3 and Figure 4).”
BackgroundInfluentialDevelopment of a PROM to measure patient-centredness in chronic care consultations in primary care
Holm, A., Lyhnebeck, A. B., Buhl, S. F., Bissenbakker, K. H., Kristensen, J. K., Møller, A., Prior, A., Kamper‐Jørgensen, Z., Böcher, S., Kristensen, M. A. T., et al. (2025) · Health and Quality of Life Outcomes · doi:10.1186/s12955-024-02327-x · Cited by 5
Klooster, B., Chatterton, K., Ibrahim, N., Bernstein, M. C., Shields, A. L., & Allen, V. D. (2025) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-024-00833-6 · Cited by 5
Fu, W., Bang, S., Huang, H., Kım, K., Li, W., An, G., Lee, J., Cai, Z., Jin, J., Wang, Y., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06303-3 · Cited by 4
“The importance of and use of PROs in clinical trials have steadily increased over time, with PRO data potentially assisting clinicians and patients during the treatment selection process in rou - tine, real-world clinical practice [20].”
Oostendorp, R. A. B., Elvers, H., van Trijffel, E., Rutten, G. M., Scholten-Peeters, G. G. M., Heijmans, M., Hendriks, E., Mikołajewska, E., Kooning, M. D., Laekeman, M., et al. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s262578 · Cited by 6
Reaney, M. D., Cline, J., Wilson, J. C., & Posey, M. C. (2020) · Patient · doi:10.1007/s40271-020-00455-2 · Cited by 5
Abu‐Zaid, A., Alshahrani, M. S., Al-Matary, A., Khadawardi, K. A., Miski, N. T., Abuzaid, M., AlRasheed, M. A., Baradwan, A., Salem, A., Salem, R. H., et al. (2022) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2022.06.028 · Cited by 4
Brock, L., Hightower, B., Moore, T. M., Nees, D., Heigle, B., Shepard, S., Kee, M. D., Ottwell, R., Hartwell, M. L., & Vassar, M. B. (2022) · Arthroscopy Sports Medicine and Rehabilitation · doi:10.1016/j.asmr.2022.04.032 · Cited by 4
Фрингс, А., Ziaei, M., Lundström, M., & Allan, B. D. (2022) · Journal of Cataract & Refractive Surgery · doi:10.1097/j.jcrs.0000000000001018 · Cited by 4
Beaumont, J. L., Lin, H. M., Goodman, E., Yu, H., Geiger, A. E., & Hudgens, S. A. (2023) · Value in Health · doi:10.1016/j.jval.2023.10.014 · Cited by 5
Effect of pedicle type on breast reduction: Clinical and patient-reported outcomes
Adebagbo, O. D., Rahmani, B., Park, J. B., Chen, A., Garvey, S. R., Lee, D., Saxena, N., Lee, B. T., Boustany, A., Lin, S. J., et al. (2024) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2024.04.012 · Cited by 4
Robertson, E. G., Hetherington, K., Daly, R., Donoghoe, M. W., Handelsman, N., Ziegler, D. S., & Wakefield, C. E. (2024) · Cancer Medicine · doi:10.1002/cam4.7339 · Cited by 5
Gerbasi, M. E., Kosinski, M. R., Meltzer-Brody, S. E., Acaster, S., Fridman, M., Huang, M., Bonthapally, V., Hodgkins, P., Kanes, S., & Eldar‐Lissai, A. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1902295 · Cited by 7
Guideline Development for Medical Device Technology: Issues for Consideration
Battelino, T., Brosius, F. C., Ceriello, A., Cosentino, F., Green, J., Kellerer, M., Koob, S., Kosiborod, M., Lalic, N. M., Marx, N., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221093355 · Cited by 5
“152 Moreover, findings from well-defined and reliable PRO instruments can be used to guide technology development and support claims in medical product labeling.”
BackgroundTherapeutic options for patients with pulmonary hypertension and interstitial lung disease
Swisher, J. W., & Weaver, E. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251335815 · Cited by 3
“123,124 At the individual patient level, PROMs have value in monitoring treatment effects and guiding modifications in the therapeutic approach.”
Franklin, M. K., Peasgood, T., & Tennant, P. W. G. (2025) · Quality of Life Research · doi:10.1007/s11136-025-04007-9 · Cited by 4
Kangwanrattanakul, K. (2025) · Health and Quality of Life Outcomes · doi:10.1186/s12955-025-02406-7 · Cited by 4
“Health-related quality of life (HRQoL) refers to a subjective evaluation of health conditions and treatments on an individual’s well-being [2, 3].”
Kiloatar, H., Demir, Ç. Ö., Delibay, A. A., Ceylan, D., & Uysal, E. S. (2025) · Acta Neurologica Belgica · doi:10.1007/s13760-025-02889-7 · Cited by 3
“These methods offer a more comprehensive per - spective on how individuals perceive their functional capac - ity in the real world by evaluating not only physical aspects but also cognitive and psychological dimensions [20].”
Kangwanrattanakul, K., & Ingard, A. (2025) · Health and Quality of Life Outcomes · doi:10.1186/s12955-025-02450-3 · Cited by 8
Blickle, P., Storz, L. M., Schmidt, M. E., Lehmann, J., Pilz, M. J., Milzer, M., Maatouk, I., Giesinger, J. M., & Steindorf, K. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116134 · Cited by 5
Himpe, J., Orije, M. R. P., Jaeghere, E. A. D., Vandecasteele, K., & Denys, H. G. (2026) · Cancers · doi:10.3390/cancers18020258 · Cited by 4
Powell, P. A., Rencz, F., Carlton, J., Kreimeier, S., Peasgood, T., Mulhern, B. J., Finch, A., Herdman, M., & Verstraete, J. (2026) · Quality of Life Research · doi:10.1007/s11136-026-04199-8 · Cited by 3
Rugo, H. S., Jhaveri, K. L., Pernas, S., Pistilli, B., Im, S., Laurentiis, M. D., Wang, S., Jañez, N. M., Borges, G., Cescon, D. W., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108330 · Cited by 4
TUNG, W. L., & Rahman, M. M. (2022) · The Indonesian Journal of Public Health · doi:10.20473/ijph.v17i2.2022.184-195 · Cited by 4
Patients' experiences of completing patient‐reported outcomes in clinical trials: An interview study
Østergaard, L. D., Nørgaard, B., Holm, M. E., Hansen, A., Lund, L. C., & Poulsen, M. H. (2023) · International Journal of Urological Nursing · doi:10.1111/ijun.12363 · Cited by 3
Ciccodicola, E. M., Liang, A., Kay, R. M., & Wren, T. A. L. (2024) · Journal of Pediatric Orthopaedics · doi:10.1097/bpo.0000000000002684 · Cited by 3
Heitkamp, H., Heußner, D., Rosenberger, D. C., Schnabel, K., Rosenthal, D. I., Bigalke, S., Maeßen, T. V., Hohenschurz‐Schmidt, D., Liedgens, H., Kaiser, U., et al. (2024) · European Journal of Pain · doi:10.1002/ejp.2272 · Cited by 5
Selective Neurectomy for Postfacial Paralysis Synkinesis: A Systematic Review
Namavarian, A., Cheng, E. Y., Shapiro, J., Ziai, H., Talei, B., Pai, A. M., Enepekides, D., & Gantous, A. M. (2024) · Facial Plastic Surgery · doi:10.1055/s-0044-1786824 · Cited by 3
“25 This is especially important for patients withPFPSas it has a signi fi cant negative impacton a patient ’ s quality of life.”
BackgroundLefkovits, Y. R., Heriot, N., Sporik, A., Perera, S., Friedlander, M. L., Dixon, C., Cohen, P. A., Lee, Y. C., Hyde, S. E., Richardson, G. E., et al. (2024) · BMC Health Services Research · doi:10.1186/s12913-024-11042-8 · Cited by 3
“As research trends progress from only including ‘hard’ end-points, such as morbidity and mortality, HRQL data adds a critical new dimension of patients’ experience of illness, capturing outcomes that are fundamentally important from their perspective [3].”
BackgroundSelf-citationKeppler, L., Navarre, F., Keppler, A. M., Ihle, C., Becker, J., Fürmetz, J., & Saier, T. (2024) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-024-05728-1 · Cited by 4
“The used questionnaires are validated, and we assume that the study design with a personalized questionnaire motivated patients to provide complete information [34–36].”
John, R. S., Spicer, S. J., Hadaya, M., Brancaccio, H., Park, S.-K., & McMillan, S. (2024) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-024-05650-6 · Cited by 3
“Patient-reported outcome measures (PROMs) are an increasingly popular endpoint in clinical trials [12].”
Bodine, B. G., Kapron, A. L., Johnson, B. T., Maak, T. G., Ernat, J. J., & Aoki, S. K. (2025) · Arthroscopy Sports Medicine and Rehabilitation · doi:10.1016/j.asmr.2025.101103 · Cited by 3
“10 While previous studies have indicated that the setting of administration can in fl uence mental health and quality-of-life scores, there are currently limited data investigating the effects of setting on physical function scores in the fi eld of orthopaedic hip preservation.”
Assessment of patient-centered outcomes in young children with differences of sex development
Ali, S., Tseretopoulou, X., & Sandberg, D. E. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102030 · Cited by 3
Bahlis, N. J., Nooka, A. K., DiBonaventura, M., Sullivan, S. T., Chaudhary, M. A., Aydin, D., & Mohty, M. (2025) · HemaSphere · doi:10.1002/hem3.70224 · Cited by 3
Greffin, K., Schmidt, S., van den Berg, N., Hoffmann, W. U., Ritter, O., Oeff, M., Schomerus, G., & Muehlan, H. (2021) · Health and Quality of Life Outcomes · doi:10.1186/s12955-021-01807-8 · Cited by 4
Lertwanich, P., Loog-in, S., Pornrattanamaneewong, C., & Ganokroj, P. (2021) · Orthopaedic Journal of Sports Medicine · doi:10.1177/23259671211042017 · Cited by 3
“Either generic or disease-specific questionnaires have been used in research and clinical practice for assessing a change in a patient’s health status after an intervention.(3,14) PROs are considered the gold standard for measuring outcomes for nonsurgical and surgical treatment.”
BackgroundMethodSoman, R. J., Singh, K., & Swamy, M. V. (2022) · International Journal of Health Sciences and Research · doi:10.52403/ijhsr.20220336 · Cited by 2
“12; Issue: 3; March 2022 efficacy and assessing the study endpoints.([41]) Participants in our study had high compliance with the treatment.”
BackgroundWouters, E., Stek, C. J., Swartz, A., Buyze, J., Schutz, C., Thienemann, F., Wilkinson, R., Meintjes, G., Lynen, L., & Nöstlinger, C. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.983028 · Cited by 5
“This is also in line with the increasing importance of including patient-reported outcomes in clinical trials as a valuable way to assess and transparently report on disease-impact in a patient-centered way (Mercieca-Bebber et al., 2018).”
Gnanasakthy, A., Norcross, L., Clark, M., & Fitzgerald, K. A. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00774 · Cited by 3
“Even when a PRO strategy is comprehensive, missing PRO data can reduce statistical power and produce biased estimates, leading to invalid conclusions and, ultimately, hindering benefit-risk analyses of new treatments.(38,41,42) In the 2019 ODAC meeting reviewing pexidartinib, for example, a reviewer noted that “althou…”
BackgroundChan, E. K. H., Williams, V. S. L., DeMuro, C., Fehnel, S. E., Slagle, A. F., Stoddard, J. J., SADOFF, J. C., Mayorga, M. A., Lewis, S., Yarr, S., et al. (2023) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-023-00581-z · Cited by 3
Deng, Y., Hu, H. H., Jia, R., Dai, W., Wang, D., Zhang, P., Zhang, P., Cheng, K., Tang, J., Yan, W., et al. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02432-5 · Cited by 3
“PRO (patient-reported outcome) is a non-traditional clinical indicator of capturing patient symptoms, functional outcomes, or health-related quality of life directly from the patients’ perspective without interpretation from others [7, 8].”
BackgroundDutt, H., Dean, A., Kamal, R. S., & Allan, A. L. (2023) · Journal of Medical Education and Curricular Development · doi:10.1177/23821205231219394 · Cited by 7
“6 In Canada, government organizations such as Cancer Care Ontario have now developed a Patient-Reported Outcomes and Symptom Management Framework to integrate PROs more formally into clinical practice.”
BackgroundCasani, A. P., Albera, R., Piras, C., Albera, A., Noto, A., Ducci, N., Atzori, L., Lucisano, S., Mussap, M., & Fanos, V. (2024) · Metabolites · doi:10.3390/metabo14020086 · Cited by 3
“…in order to claim the status of the main outcome measure, we asked patients about the efficacy (relief of symptoms) and tolerability (patient perspective of adverse drug reactions) of the treatment, reported as excellent, good, sufficient or poor (patient-oriented outcome measures) [35,36].”
BackgroundTang, K., Sutherland, J. M., Liu, G., Crump, T., Bazzarelli, A., Dingee, C. K., Pao, J., Warburton, R., & McKevitt, E. C. (2024) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2024.02.012 · Cited by 3
Burbage, S. C., Krupsky, K. L., Cambron‐Mellott, M. J., Way, N., Patel, A. A., & Liu, J. J. (2024) · Crohn s & Colitis 360 · doi:10.1093/crocol/otae021 · Cited by 3
“15 As IBD is an under-recognized condition in minority patient groups, PROs can allow data collection from a diverse patient population.”
BackgroundShwan, A., Lamidi, S., Chan, C., Daniels, E., Song-Smith, C., Hanna, L., Sounderajah, V., Houghton, J. S. M., & Sayers, R. D. (2024) · BJS Open · doi:10.1093/bjsopen/zrae126 · Cited by 5
“Future research assessing quality of individual outcomes measures (for example, reliability, validity) of varying types of outcome measures (for example, PROMs) is required as part of implementation of a COS, once developed.”
BackgroundInfluentialLoubert, A., Regnault, A., Sebille, V., & Hardouin, J.-B. (2022) · BMC Medical Research Methodology · doi:10.1186/s12874-022-01680-z · Cited by 4
“PRO scores are increasingly used as key end-points to demonstrate the efficacy of new treatments in randomized clinical trials [2].. PRO scores are produced based on a scoring algorithm, or scoring rules.”
Fernandes‐Taylor, S., Smith, C. D., Arroyo, N., Bonnet, K. R., Schlundt, D. G., Wichmann, M. A., Feurer, I. D., & Francis, D. O. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030151 · Cited by 3
Rosa, G. R. M. L. (2024) · Evidence-Based Dentistry · doi:10.1038/s41432-024-01034-2 · Cited by 3
“The utility of PROs lies in their ability to provide unique insights into the patient ’ s experience, enhancing the quality of care and research outcomes by incorporating the patient ’ s perspective on symptoms, treatment ef fi cacy, and overall health-related quality of life (HRQoL) 2 .”
Jayasinghe, R. T., Ahern, S., Maharaj, A. D., Romero, L., & Ruseckaite, R. (2024) · JMIR Research Protocols · doi:10.2196/52572 · Cited by 2
“PROMs in clinical trials are important for decision-making among the stakeholders involved, especially in medical device-related trials to measure adverse events and other negative outcomes to assess the safety of a medical device [10].”
BackgroundRodrigues, A., Abi‐Nader, S., Durand, R., Rompre, P. H., Janati, A. I., Atsü, S., Morris, M., & Emami, E. (2024) · Systematic Reviews · doi:10.1186/s13643-024-02561-w · Cited by 5
A Bibliometric Analysis of the Top 100 Papers on Gluteal Augmentation
Daneshi, K., Mansour, H. R. K., Pacheco-Barrios, N. V., Asaju, A., Pachon, M. P., Hoyos, A. E., & Khajuria, A. (2024) · Aesthetic Surgery Journal Open Forum · doi:10.1093/asjof/ojae053 · Cited by 2
“119 The strength of this study lies in its exhaustive analysis of the worldwide research landscape on gluteal grafting, shedding light on prevailing trends, geographical variances, and thematic concentrations within the domain.”
BackgroundMagnusson, C., Ölfvingsson, E., Hjortswang, H., Balkhed, Å. Ö., & Serrander, L. (2024) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2024.2415694 · Cited by 2
“Patient-reported outcomes are increasingly recognized as essential endpoints for clinical research [20].”
Newington, L., Ceh, D., Sandford, F. M., Parsons, V., & Madan, I. (2024) · Journal of Occupational Rehabilitation · doi:10.1007/s10926-024-10251-6 · Cited by 3
“Many of the included studies used patient-reported outcomes, which are a key component of both patient-centred care and healthcare research [61].”
Nair, N. P. V., Abou-Farhat, M., Kaur, N., Jones, N., Mohan, G., Boruff, J. T., & Iyer, S. N. (2025) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgae032 · Cited by 2
“8,9 Particularly if co-developed with service users, patient-reported measures have the potential to make patient values, priorities, preferences, and perspectives visible.”
Regnault, A., Loubert, A., Quéré, S., Lin, Q., Frick, G. S., Ishida, H., Abeta, Y., & Chevrou‐Séverac, H. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1463938 · Cited by 2
Saade, J., van Wyk, A., Stebbins, G. T., & Mestre, T. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70007 · Cited by 2
“11 Currently, there is no PRO that comprehensively addresses the multidimensional and evolving nature of symptoms in the prodromal and early motor stages of PD.”
Nestler, S., Apfelbacher, C., Özkan, E., Naber, K. G., & Piontek, K. (2025) · World Journal of Urology · doi:10.1007/s00345-024-05406-2 · Cited by 2
“The assessment of the effectiveness of such remedies in clinical trials from the patient’s perspective is considered crucial [4], and growing consensus has emerged about the use of standardized questionnaires (patient-reported outcome measures; PROMs) for this purpose [5].”
Sauchelli, S., Levy, C., Gnanasakthy, A., Dave, V., Doward, L. C., Fitzgerald, K. A., & Carson, R. T. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1536401 · Cited by 2
Effect of timed exercise interventions on patient-reported outcome measures: A systematic review
Karavetian, M., Khoury, C. F. E., Rutters, F., Slebe, R., Lorenzetti, D., Blondin, D. P., Carpentier, A. C., Després, J., Hoeks, J., Kalsbeek, A., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321526 · Cited by 2
“Understanding PROMs related to a certain treatment can help improve treatment protocols and facilitate mobilization of interventions into clinical practice and real-life situations and thus, achieve higher likelihood of adoption and adherence to the studied intervention [12].”
Longitudinal Modeling in Surgical Oncology Research: A Primer Examining Patient‐Reported Outcomes
Levy, J., Amakiri, U. O., Shammas, R. L., Graziano, F. D., Nelson, J. A., & Boe, L. A. (2025) · Journal of Surgical Oncology · doi:10.1002/jso.70006 · Cited by 2
Gregg, A. C., Creber, R. M., Spertus, J. A., Stone, G. W., & Gaudino, M. F. L. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001239 · Cited by 2
van Gils, P. C. W., Sep, S. J. S., Cremers, C. H. P., van Wijnen, M., Hofmeijer, J., & Heugten, C. M. V. (2025) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2025.2535582 · Cited by 3
“The importance of including PRO’s in clinical research receives growing recognition (Mercieca-Bebber et al., 2018).”
Varghese, J. J., Jacob, R., Krishnan, J. B., Aithal, V. U., Sharan, K., & Rajashekhar, B. (2025) · Logopedics Phoniatrics Vocology · doi:10.1080/14015439.2025.2545752 · Cited by 3
“Patient-reported outcome measures (PROMs) are a valuable tool for assessing patients’ opinions on their health status or overall well-being [5].”
Randhawa, S., Gater, A., Bentley, R., Cook, K. F., Hernandez-Aldama, L., King‐Kallimanis, B. L., Perfetto, E. M., Powers, J. H., Rice, G. K., Snyder, C. F., et al. (2025) · Value in Health · doi:10.1016/j.jval.2025.08.008 · Cited by 7
Aljabali, A. A. A., Obeid, M. A., Gammoh, O., Alshaer, W., Qnais, E. Y., Alqudah, A. M., Mishra, V. K., Mishra, Y., & El‐Tanani, M. (2025) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2025.2571722 · Cited by 2
Gandara, D. R., Gogishvili, M., Sezer, A., Makharadze, T., Gümüş, M., Zhu, C., Yan, E. W. C., Gullo, G., Rietschel, P., & Quek, R. G. W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1640595 · Cited by 2
Brunner, H. I., Alexeeva, E. I., Bandeira, M., Carrasco, R., Chaitow, J., Chiraseveenuprapund, P., Ting, T. V., Ergüven, M., Gottlieb, B. S., de Oliveira, S. K. F., et al. (2025) · Arthritis & Rheumatology · doi:10.1002/art.43428 · Cited by 2
“15 Encouraged by regulatory authorities, 16 the inclusion of PROs in clinical trials has increased over time, 17 and assessment of HRQoL and other PRO measures is considered essential to fully assess the bene fi ts of JIA treatments in both research and routine clinical care.”
Skovfoged, M. M., Mavromati, K., Tvrdá, L., Quinn, T. J., Körner, F., Chiesurin, S., Némcová, V., Mikulík, R., & Knoche, H. O. (2026) · ACM Transactions on Computing for Healthcare · doi:10.1145/3799983 · Cited by 2
“Yet, most hospitals have poor insight into patient longitudinal recovery [113], preventing them from: 1) optimising their care quality to improve long-term outcomes [70] and 2) intervening at onsets of health declines [29].”
Fares‐Otero, N. E., Furukawa, Y., Sijbrandij, M., Leucht, S., Vieta, E., Cuijpers, P. J., Harrer, M., & Seedat, S. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112802 · Cited by 2
Shahraz, S., Wong, O. Y., Chotai, R., Knight, S., Globe, D., Patel, M. J., Kaushik, A., Aiyegbusi, O. L., & Calvert, M. (2026) · BMJ Oncology · doi:10.1136/bmjonc-2025-000942 · Cited by 3
Self-citationAre existing quality‐of‐life instruments in cutaneous T‐cell lymphoma of sufficient quality?
Gabes, M. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19408 · Cited by 2
Balitsky, A. K., D’Souza, A., & Levine, M. N. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13774 · Cited by 2
“, the PROM selected captures how a patient feels and functions in relation to their disease(32)); PROM burden on respondent, which can affect adherence; mode of administration and associated costs, and availability of PROM in different languages.(30) A recent qualitative study on the barrier to clinical PROM use ident…”
BackgroundBaudelet, M., den Steen, L. V., Wouters, S., Bodt, M. S. D., Vanderveken, O. M., Duprez, F., & Nuffelen, G. V. (2022) · B-ENT · doi:10.5152/b-ent.2022.22989 · Cited by 2
Alrasheed, M. A., Guo, J. J., Lin, A. C., Wigle, P. R., Hardee, A. M., & Hincapie, A. L. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00957-z · Cited by 2
“Also, this type of data can highlight the patients’ unmet needs and help with informed decision making throughout care delivery [38].”
BackgroundAntunes, A., Racha-Pacheco, R., Esteves, C., Tavares, A., Mendez, J., Pacheco, P., & Short, D. (2023) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-023-00584-w · Cited by 3
Foppiani, J., Alvarez, A. H., Stearns, S. A., Taritsa, I. C., Weidman, A. A., Valentine, L., Escobar‐Domingo, M. J., Foster, L., Schuster, K. A., Ho, O. A., et al. (2024) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2024.01.036 · Cited by 3
People first: a participatory community approach on patient-reported outcomes in tuberculosis
Martín, D., Barbosa, P., Ramos, J. P., Vieira, M., & Duarte, R. (2024) · Breathe · doi:10.1183/20734735.0138-2023 · Cited by 2
“Conduct studies on the impact of infectious diseases, like TB, on patients ’ quality of life, wellbeing, and overall health outcomes using PROs [9, 10]”
BackgroundMethodFurther psychometric evaluation of the WOUND‐Q: A responsiveness study
Gallo, L., Rae, C. S., Voineskos, S. H., Simonsen, N. V., Pusic, A. L., Poulsen, L., Sørensen, J. A., Klassen, A. F., & Cano, S. (2024) · Wound Repair and Regeneration · doi:10.1111/wrr.13179 · Cited by 2
Dhaenens, B. A. E., van Dijk, S. A., Fertitta, L., Taal, W., Wolkenstein, P., & Oostenbrink, R. (2024) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-024-00732-w · Cited by 2
“While objective trial endpoints like the number and size of tumours provide information on physiologic disease severity, PROs reflect the patient’s perspective [9].”
BackgroundSrinivasan, R., Rodgers‐Melnick, S. N., Rivard, R. L., Kaiser, C. E., Vincent, D., Adan, F., & Dusek, J. A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303985 · Cited by 3
“PRO collection has drastically increased over the last decade, with numerous professional societies encouraging their use in clinical care and research [26], especially in the midst of a shift towards value-based care reimbursement [25].”
BackgroundThe State of Patient-Reported Outcome Measures in Rheumatology
Manswell, K., Le, V., Henry, K. A., Casey, M., Anumolu, N., & Putman, M. (2024) · The Journal of Rheumatology · doi:10.3899/jrheum.2023-1073 · Cited by 5
“6,8 11-13 Multiple prior studies have emphasized their importance 14-16 and professional societies, including the European Alliance of Associations for Rheumatology and the ACR, have affirmed their value in informing clinical practice, highlighting ongoing research needs, strengthening the…”
Klassen, A. F., Mansouri, J., Kaur, M. N., Rae, C. S., Poulsen, L., Dayan, S. H., Cano, S., & Pusic, A. L. (2024) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.16465 · Cited by 4
“57”
Verlis, K. M., McCaffery, K. J., Copp, T., Dodd, R. H., Laidsaar‐Powell, R., & Nickel, B. (2024) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-024-00755-3 · Cited by 2
“The use of QoL measures, physical wellbeing and health literacy measures have been single items adapted from other questionnaires and surveys (e.g., QLQ-C30, SF-36) and been validated and have demonstrated high internal consistency in previous studies involving healthcare consumers [18–21].”
MethodEAR-Q outcomes in healthy adults: determining normative data
Wolters, A. J. P., de Henau, M., & Piatkowski, A. A. (2024) · European Journal of Plastic Surgery · doi:10.1007/s00238-024-02232-y · Cited by 2
“The identification of meaningful PROM endpoints relies on the availability of normative data [12].”
Metadata
- Authors
- Mercieca-Bebber, R., King, M. T., Calvert, M. J., Stockler, M. R., & Friedlander, M.
- Affiliations
- The University of Sydney (AU)
- National Institute for Health and Care Research (GB)
- Corresponding author
- Friedlander, Michael
- Venue
- Patient Related Outcome Measures
- Publisher
- Informa UK Limited
- Published
- 2018-11
- Volume
- Volume 9
- Pages
- 353-367
- ISSN
- 1179-271X (ISSN-L)
- PMC
- PMC6219423
- OpenAlex
- W2899320385
- Cited by
- 659
- References
- 73
- Citations by year
- 2026: 77 · 2025: 129 · 2024: 138 · 2023: 88 · 2022: 85 · 2021: 75 · 2020: 54 · 2019: 12
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Related Outcome Measures (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- University Hospitals Birmingham NHS Foundation Trust
- Australian Government
- National Institute for Health and Care Research
- University of Birmingham
- Cancer Australia
- Surgical Reconstruction and Microbiology Research Centre
- National Health and Medical Research Council
- Birmingham Biomedical Research Centre
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- patient-reported outcomes, clinical trial endpoints, missing data, protocol design, patient-centered outcomes, regulatory guidelines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.